Northwestern University Human Resources
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1851-01-28
- Employees
- 5K
- Market Cap
- -
Grit Biotechnology to Present Breakthrough Immunotherapy Advances at ASGCT 2025
• Grit Biotechnology will showcase three innovative research programs at the ASGCT 2025 Annual Meeting, including an APC-targeted neoantigen cancer vaccine, non-viral in vivo CAR-T therapy, and LNP-mediated gene editing in TILs.
• The presentations, developed in collaboration with Vitalgen BioPharma, demonstrate significant advancements in precision delivery technologies for next-generation immunotherapies targeting solid tumors.
• Grit Bio's clinical pipeline includes GT101, the first TIL therapy in pivotal Phase II trials, and GT201, the first TIL therapy with membrane-bound IL-15 complex that has received IND clearance in both US and China.
Pregnancy Complications Linked to Increased Heart Disease Risk in Women and Their Sisters
• New research from the Karolinska Institute reveals that women who experience pregnancy complications face higher long-term cardiovascular disease risks, suggesting important implications for preventive care.
• The groundbreaking "Sister Study" demonstrates that even sisters of women with pregnancy complications have a 40% higher risk of heart issues, indicating a significant genetic component to these health risks.
• Women who deliver twins face double the risk of hospitalization for heart problems within a year compared to those with singleton pregnancies, with risk increasing eightfold if high blood pressure was present during pregnancy.
Omeros Forms Elite Clinical Steering Committee to Advance Novel AML Therapeutic Program
• Omeros Corporation has established an Oncology Clinical Steering Committee comprising eight distinguished leukemia experts from leading cancer centers to guide its OncotoX-AML program development.
• The OncotoX-AML therapeutic has demonstrated superior efficacy to current standard treatments in preclinical studies, effectively targeting 90% of common AML mutations while showing excellent tolerability at high doses.
• The novel engineered molecules, approximately half the size of antibodies, selectively kill dividing cancer cells including treatment-resistant leukemia stem cells, addressing a significant unmet need in AML treatment.
BriaPro Develops Novel Antibodies Targeting B7-H3 for Multi-Cancer Immunotherapy Applications
• BriaPro Therapeutics, a subsidiary of BriaCell, has developed novel high-affinity antibodies targeting B7-H3, a protein overexpressed in multiple solid tumors while showing limited expression in normal tissues.
• The company plans to incorporate these antibodies into its Bria-TILsRx platform, which integrates T cell engagers and immune checkpoint modulators to enhance anti-tumor activity within the tumor microenvironment.
• BriaPro has filed provisional US patent applications for this technology and intends to develop it into antibody-drug conjugates, T cell engagers, and targeted immune checkpoint inhibitors for multiple cancer indications.
ALS Drug NU-9 Shows Promising Results for Alzheimer's Disease in Animal Study
• Northwestern University researchers found that NU-9, an experimental drug approved for ALS clinical trials, effectively reduces toxic protein buildup in Alzheimer's disease animal models.
• The drug works by enhancing cellular recycling mechanisms, specifically targeting lysosomes and the enzyme cathepsin B to break down harmful protein clusters that cause neurodegeneration.
• NU-9 demonstrated dual benefits in animal studies: reducing amyloid beta oligomer accumulation and decreasing brain inflammation, with treated mice showing improved performance on memory tests.
Northwestern Medicine Launches Landmark Study Using Apple Watch to Revolutionize AFib Treatment
• Northwestern Medicine researchers are initiating a seven-year clinical trial to determine if wearable technology can reduce continuous blood thinner use in atrial fibrillation patients, potentially decreasing bleeding risks and improving quality of life.
• The REACT-AF trial will monitor participants using Apple Watch technology, implementing a "pill-in-pocket" approach where patients take anticoagulants only during detected AFib episodes rather than daily for life.
• With AFib affecting over 5 million Americans and expected to reach 12.1 million by 2030, this NIH-funded study could fundamentally change treatment standards by personalizing anticoagulation therapy based on real-time heart rhythm monitoring.
Sibel Health Secures $30 Million Series C Funding and New FDA Clearance for Interoperable Monitoring Platform
• Sibel Health has closed a $30 million Series C financing round led by the Steele Foundation for Hope with significant participation from Dräger, positioning the company for commercial expansion.
• The company received its 7th FDA 510(k) clearance for the ANNE® One platform, enabling alarms and alerts with a central station, and notably achieving compliance with the IEEE SDC 11073 interoperability standard.
• Northwestern Medicine has acquired ANNE® One systems to evaluate improvements in nursing workflow and patient sleep quality using Sibel's wireless wearable sensors for continuous vital sign monitoring.
Moderna and Pfizer/BioNTech Locked in Escalating mRNA Patent Battle with Billions at Stake
• Moderna has filed patent infringement lawsuits against Pfizer/BioNTech in multiple countries, claiming their Comirnaty vaccine infringes on mRNA technology patents that Moderna pioneered and invested billions in developing.
• The legal battle has expanded globally with Moderna scoring a recent victory in Germany, while simultaneously suffering defeats at the USPTO's Patent Trial and Appeal Board where some of its patents were found unpatentable.
• With combined COVID-19 vaccine sales exceeding $100 billion, the financial stakes are enormous, as evidenced by significant settlements already reached with NIH—$400 million from Moderna and $791.5 million from BioNTech.
Northwestern's Lurie Cancer Center Joins Clinical Trial Testing LIXTE's LB-100 Plus Dostarlimab for Ovarian Clear Cell Cancer
• Northwestern University's Lurie Cancer Center has been added as the second site in LIXTE Biotechnology's clinical trial combining LB-100 with GSK's dostarlimab for ovarian clear cell cancer treatment.
• The first patient has been successfully dosed at Lurie Cancer Center under the leadership of Dr. Emily M. Hinchcliff, marking an important expansion of the study initially launched at MD Anderson Cancer Center.
• The trial aims to evaluate whether LIXTE's proprietary PP2A inhibitor LB-100 can enhance immunotherapy effectiveness in treating ovarian clear cell carcinoma, addressing a significant unmet medical need.
HealthBio Launches FDA Fast-Track Trial for Long COVID Treatment Using Maraviroc-Atorvastatin Combination
• HealthBio initiates Phase III clinical trial testing a novel combination of Selzentry (maraviroc) and Lipitor (atorvastatin) for Long COVID treatment, involving 252 patients in a randomized, double-blind study.
• The company's approach targets vascular inflammation through CCR5 pathway modulation, supported by preliminary data showing promising results in over 12,000 treated patients.
• With $10M initial funding and FDA Fast-Track designation, the trial aims to address a condition affecting up to 23 million Americans and causing an estimated $3.7 trillion economic impact.
Landmark Prevention Trial Launches to Stop Alzheimer's Before Symptoms Begin in Young Adults
• WashU Medicine initiates groundbreaking international trial testing Eli Lilly's remternetug in young adults as young as 18, targeting Alzheimer's prevention up to 25 years before expected symptom onset.
• The Primary Prevention Trial will enroll 240 participants from families with genetic mutations, focusing on removing or preventing amyloid beta plaques before cognitive symptoms develop.
• The $130 million study represents a collaborative effort between academic institutions, pharmaceutical industry, and foundations, with support from NIH, Alzheimer's Association, and private donors.
FDA Clears Northwestern University's IND Application for Calidi's Novel Glioma Treatment CLD-101
• The FDA has cleared Northwestern University's IND application for Calidi Biotherapeutics' CLD-101, a stem cell-based platform delivering oncolytic viruses for treating high-grade glioma, with Phase 1b/2 trials starting late 2024.
• Previous Phase 1 trials demonstrated promising results with median progression-free survival of 9.05 months and overall survival of 18.4 months, showing no dose-limiting toxicity.
• The treatment addresses a critical unmet need in high-grade glioma patients, who currently face a challenging five-year survival rate of only 5-10% with conventional therapies.
Moleculin Biotech's Annamycin Shows Promise in Overcoming Treatment Resistance in AML
• Moleculin Biotech's Annamycin demonstrates the ability to overcome resistance to Venetoclax in acute myeloid leukemia (AML) based on preclinical and clinical data.
• Preliminary clinical data from the MB-106 trial indicates a 60% complete remission rate in relapsed or refractory AML patients treated with Annamycin plus Ara-C.
• Moleculin has received regulatory approval in Europe to begin recruiting for its Phase 3 MIRACLE trial, evaluating Annamycin in combination with Cytarabine for R/R AML.
• The FDA has provided positive guidance on Moleculin's IND amendment, potentially accelerating the approval timeline for Annamycin in AML treatment.
© Copyright 2025. All Rights Reserved by MedPath